GSK Logo


This site is intended for members of the healthcare profession in Ireland only. Otherwise see Public Site


0.5mg dutasteride / 0.4mg tamsulosin hydrochloride

Product overview >

Information overview of Combodart™, including what Combodart™ is and the administration of Combodart™.


Prescribing Combodart™ >

Information on prescribing Combodart™, including Combodart™’s indications, efficacy and safety information.


Clinical evidence >

Information on the clinical evidence of Combodart™, including CombAT data.


Mode of Action >

An infographic video showing what Combodart™ is, how Combodart™ works and how Combodart™ targets the
underlying cause of BPH.

For further information about GSK’s urology portfolio for the treatment of benign prostatic hyperplasia (BPH), please visit our Urology section.

left image
Member of Irish Public
right image
Irish Healthcare Professional*
GSK Health logo



0.5mg dutasteride / 0.4mg tamsulosin hydrochloride

Important Notice: This site is intended for Healthcare Professionals Registered in the Republic of Ireland only. By entering this site you are confirming that you are a Healthcare Professional. GM: Last Updated March 2015: IE/DUTT/0039/15

Adverse events associated with Combodart include impotence, decreased libido, ejaculation disorders, breast tenderness and enlargement, and dizziness. Men taking Combodart should be regularly evaluated for prostate cancer risk including PSA testing. Any confirmed increase from lowest PSA level while on Combodart may signal the presence of prostate cancer or noncompliance to therapy with Combodart and should be carefully evaluated. For additional/complete safety information, please refer to the prescribing information for Combodart.
Combodart™ is a registered trademark of the GlaxoSmithKline Group of Companies
Adverse events should be reported directly to the HPRA; Freepost, Pharmacovigilance Section, Health Products Regulatory Authority, Earlsfort Terrace, Dublin 2, Tel: +353 1 676 4971, Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

KC: Updated October 2014: IE/DUTT/0033/14b